UnitedHealth (UNH) Faced a Significant Downturn in Q2. Here’s Why

Wedgewood Partners' Q2 2025 investor letter reported a 7.1% net return, significantly underperforming the S&P 500 and Russell 1000 Growth, primarily due to UnitedHealth Group (UNH) being a leading detractor. The firm liquidated its UNH holdings, citing spiking medical costs in Medicare Advantage from misjudged member morbidity, execution failures at Optum Health, the company's subsequent withdrawal of 2025 earnings guidance, and key management turnover including the CEO, which collectively questioned UNH's long-term growth trajectory. This decision follows UNH's nearly 50% share price decline over the past year and a observed reduction in overall hedge fund interest, signaling a significant re-evaluation of the healthcare sector bellwether.

Analysis

UnitedHealth Group (UNH) has been identified as a significant performance detractor by investment manager Wedgewood Partners, prompting the complete liquidation of their position. The decision was driven by severe operational and management issues, including unexpectedly spiking medical costs in its core Medicare Advantage business due to a misjudgment of member morbidity, and execution failures at its Optum Health segment. These missteps, described as rare for a company previously viewed as a high-quality operator, led to the withdrawal of the company's 2025 earnings guidance and the turnover of key management, including the CEO. This reflects a profound loss of confidence in the company's previously assumed double-digit growth trajectory. The negative sentiment is corroborated by broader market data, which shows a decline in hedge fund ownership from 150 to 139 portfolios in the prior quarter, alongside a precipitous 49.04% drop in share value over the last 52 weeks.

Key Decisions for Investors

• Current UNH shareholders should critically reassess their investment thesis, as the combination of operational failures, management turnover, and withdrawn earnings guidance fundamentally questions the company's long-term growth trajectory.
• Potential investors should exercise extreme caution, as the lack of forward guidance and leadership instability introduce significant risk; any new position should be deferred until the company provides clarity on medical cost trends and a new strategic direction.
• The decision by an institutional investor to liquidate its holdings, coupled with a decline in overall hedge fund ownership, represents a significant negative sentiment shift that warrants serious consideration before initiating or adding to a position.